Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-07-29), Corcept Therapeutics's 12-1 Month Momentum % is 27.47%.
The industry rank for Corcept Therapeutics's 12-1 Month Momentum % or its related term are showing as below:
FRA:HTD's 12-1 Month Momentum % is ranked better than 73.4% of 1361
companies
in the Biotechnology industry
Industry Median: -20.29
vs FRA:HTD: 27.47
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Corcept Therapeutics 12-1 Month Momentum % Related Terms
FRA:HTD vs APGE, KRYS, NUVL: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, Corcept Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics (FRA:HTD) has a 12-1 Month Momentum % of 27.47% as of Jul. 29, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Corcept Therapeutics and its competitors. According to the industry distribution chart, Corcept Therapeutics ranks #362 out of 1361 companies in the Biotechnology industry, placing it in the top 26.6%.
Is Corcept Therapeutics' 12-1 Month Momentum % too high?
Corcept Therapeutics' current 12-1 Month Momentum % is 27.47%. Based on the distribution chart, Corcept Therapeutics ranks #362 out of 1361 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Corcept Therapeutics has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' 12-1 Month Momentum % compare to APGE and KRYS?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #362 out of 1361 companies for 12-1 Month Momentum %. This puts Corcept Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current 12-1 Month Momentum % is 27.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (FRA:HTD) is currently considered Significantly Overvalued. The stock's GF Value™ is €54.10, compared to a current price of €78.78 — trading 45.6% above its estimated fair value. The current 12-1 Month Momentum % is 27.47%. Corcept Therapeutics' overall GF Score™ is 85/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Corcept Therapeutics (FRA:HTD), the current 12-1 Month Momentum % is 27.47% as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (FRA:HTD) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of €78.78 is trading 45.6% above its estimated GF Value™ of €54.10.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:HTD:
12-1 Month Momentum %: 27.47%
GF Value™: €54.10 vs. price of €78.78 (45.6% above fair value)
No single metric tells the full story. See the FRA:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score
Get the complete analysis for FRA:HTD
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HTD has been successfully added to your 
